Mumps virus strain B level jeryl lynn live antigen
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Mumps virus strain B level jeryl lynn live antigen is a vaccine used to prevent Mumps.
- Brand Names
- M-M-R II, Proquad
- Generic Name
- Mumps virus strain B level jeryl lynn live antigen
- DrugBank Accession Number
- DB10316
- Background
Mumps virus strain B level jeryl lynn live antigen is a live attenuated virus vaccine for subcutenous injection. It is an active immunization against mumps, which is a common childhood disease.
- Type
- Biotech
- Groups
- Approved, Investigational
- Biologic Classification
- Vaccines
Attenuated - Synonyms
- Mumps Virus Vaccine Live, Jeryl Lynn Strain
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image M-M-R II Mumps virus strain B level jeryl lynn live antigen (12500 [TCID_50]/0.5mL) + Measles virus vaccine live attenuated (1000 [TCID_50]/0.5mL) + Rubella virus vaccine (1000 [TCID_50]/0.5mL) Injection, powder, lyophilized, for suspension Subcutaneous A-S Medication Solutions 1971-04-21 Not applicable US 
M-M-R II Mumps virus strain B level jeryl lynn live antigen (12500 TCID50/0.5mL) + Measles virus vaccine live attenuated (1000 TCID50/0.5mL) + Rubella virus vaccine (1000 TCID50/0.5mL) Powder, for solution Subcutaneous Merck Ltd. 1979-12-31 Not applicable Canada 
M-M-R II Mumps virus strain B level jeryl lynn live antigen (12500 [TCID_50]/0.5mL) + Measles virus vaccine live attenuated (1000 [TCID_50]/0.5mL) + Rubella virus vaccine (1000 [TCID_50]/0.5mL) Injection, powder, lyophilized, for suspension Subcutaneous Physicians Total Care, Inc. 1996-08-07 2012-06-30 US M-M-R II Mumps virus strain B level jeryl lynn live antigen (12500 [TCID_50]/0.5mL) + Measles virus vaccine live attenuated (1000 [TCID_50]/0.5mL) + Rubella virus vaccine (1000 [TCID_50]/0.5mL) Injection, powder, lyophilized, for suspension Subcutaneous Merck Sharp & Dohme Corp. 1971-04-21 Not applicable US M-M-rvaxpro Mumps virus strain B level jeryl lynn live antigen (12500 TCID50) + Measles virus vaccine live attenuated (1000 TCID50) + Rubella virus vaccine (1000 TCID50) Msd Vaccins 2021-02-10 Not applicable EU 
M-M-rvaxpro Mumps virus strain B level jeryl lynn live antigen (12500 TCID50) + Measles virus vaccine live attenuated (1000 TCID50) + Rubella virus vaccine (1000 TCID50) Msd Vaccins 2021-02-10 Not applicable EU M-M-rvaxpro Mumps virus strain B level jeryl lynn live antigen (12500 TCID50) + Measles virus vaccine live attenuated (1000 TCID50) + Rubella virus vaccine (1000 TCID50) Msd Vaccins 2021-02-10 Not applicable EU M-M-rvaxpro Mumps virus strain B level jeryl lynn live antigen (12500 TCID50) + Measles virus vaccine live attenuated (1000 TCID50) + Rubella virus vaccine (1000 TCID50) Msd Vaccins 2021-02-10 Not applicable EU M-M-rvaxpro Mumps virus strain B level jeryl lynn live antigen (12500 TCID50) + Measles virus vaccine live attenuated (1000 TCID50) + Rubella virus vaccine (1000 TCID50) Msd Vaccins 2021-02-10 Not applicable EU M-M-rvaxpro Mumps virus strain B level jeryl lynn live antigen (12500 TCID50) + Measles virus vaccine live attenuated (1000 TCID50) + Rubella virus vaccine (1000 TCID50) Injection, powder, for suspension Intramuscular; Subcutaneous Msd Vaccins 2021-02-10 Not applicable EU
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 47QB6MX9KU
- CAS number
- Not Available
References
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Not Available Rheumatoid Arthritis, Juvenile 1 4 Completed Prevention Adverse Event Following Immunization / Measles / Mumps / Rubella 1 4 Completed Prevention BCG Infection / Immune Responses / Vaccine Reaction 1 4 Completed Prevention Chickenpox / Hepatitis A / Measles / Mumps / Rubella 1 4 Completed Prevention Encephalitis, Japanese B / Measles / Mumps / Rubella 1 4 Completed Prevention Hepatitis A Virus 1 4 Completed Prevention Hepatitis A / Measles / Mumps / Rubella 1 4 Completed Prevention Measles / Mumps / Rubella 2 4 Completed Prevention Mumps 1 4 Completed Treatment Human Immunodeficiency Virus (HIV) Infections 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, powder, lyophilized, for solution Subcutaneous Injection, powder, lyophilized, for suspension Subcutaneous Injection, powder, for suspension Intramuscular; Subcutaneous Injection, powder, lyophilized, for solution Intramuscular; Subcutaneous Injection, powder, for solution Subcutaneous Kit; powder, for solution Intramuscular; Subcutaneous Injection, solution Intramuscular; Subcutaneous Injection, powder, for solution Intramuscular; Subcutaneous Injection Powder, for solution Subcutaneous Injection, powder, lyophilized, for suspension Intramuscular; Subcutaneous Injection Subcutaneous Solution Injection, powder, lyophilized, for suspension Powder - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created on December 01, 2015 20:03 / Updated on June 12, 2020 16:53